Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22-MedSci.cn

Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22

Siefker-Radtke, AO; Lugowska, I; Tupikowski, K; Andric, ZG; Kalebasty, AR; Curigliano, G; Vaena, D; Vogl, FD; Currie, G; Abella, S; Kelly, W

ANNALS OF ONCOLOGY, 2019; 30 (): 365

科室
- - 订阅+
  - 更多科室
工具
服务